1st Quarter - Report

INFECTIOUS DISEASES SOCIETY OF AMERICA for INFECTIOUS DISEASES SOCIETY OF AMERICA

Firm
Client
Income
—
Expenses
$175,131
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests

LobbyistCovered position, as disclosed
AMANDA JEZEK V.P. Public Policy & Government Relations
JONATHAN NURSE Government Relations Director

Contacted: Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); SENATE; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA)

Medicare/Medicaid MMM

Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform

LobbyistCovered position, as disclosed
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
JONATHAN NURSE Government Relations Director

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE; Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH)

Budget/Appropriations BUD

Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.

LobbyistCovered position, as disclosed
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
JONATHAN NURSE Government Relations Director

Contacted: Agency for Healthcare Research & Quality (AHRQ); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA)

Health Issues HCR

Infectious diseases; drug, diagnostics and vaccine R&D; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research; reauthorization of PEPFAR; Lyme diseases and other infectious diseases issues; Ryan White reauthorization; PDUFA; ADAPT Act; DISARM Act; PATH Act; PARA Act

LobbyistCovered position, as disclosed
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
JONATHAN NURSE Government Relations Director

Contacted: SENATE; Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Medical/Disease Research/Clinical Labs MED

Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants

LobbyistCovered position, as disclosed
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
JONATHAN NURSE Government Relations Director

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Agency for Healthcare Research & Quality (AHRQ); Natl Institutes of Health (NIH); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.